Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study (BOLD)

Waikato Hospital

Status: Completed

Conditions: Chronic Obstructive Pulmonary Disease

Treatments: Drug: bronchodilator response

Study type: Interventional

Funder types: Other

Identifiers

NCT00745043

NTX/05/04/035

Details and patient eligibility

About

Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These are very common conditions and many patients have both diseases. Beta-blocker drugs are extensively used in the treatment of angina, high blood pressure and after heart attacks to decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in COPD patients as they may make the breathlessness worse, but it has now been established that they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the body and the investigators do not know if they can work together or if they would cancel each other out. The investigators also do not know which of the different types of beta-blockers now available are better for COPD patients. This study will investigate what happens to the airways of people taking both of these drugs.

Enrollment: 11 patients

Sex: All

Ages: 40 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of COPD
• > 40 years of age
• > 15 pack year smoking history

Exclusion criteria

• Contra-indication to beta-blocker use
• Severe COPD FEV1 < 30% or 1 L
• Not responsive the methacholine

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

11 participants in 4 patient groups, including a placebo group

R302

Placebo Comparator group

Description:

Daily placebo capsules

Treatment:

Drug: bronchodilator response

R303

Active Comparator group

Description:

Daily metoprolol 95mg capsules

Treatment:

Drug: bronchodilator response

R304

Active Comparator group

Description:

Daily propranolol 80mg capsules

Treatment:

Drug: bronchodilator response

Open Label

Active Comparator group

Description:

Daily Metoprolol 190mg capsules

Treatment:

Drug: bronchodilator response